-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Mirati Therapeutics announced that its KRAS G12C inhibitor adagasib has achieved positive results in the KRYSTAL-1 Phase II clinical trial
In a cohort of previously treated patients with pancreatic duct adenocarcinoma and other gastrointestinal (GI) cancers with KRAS G12C mutation, adagasib demonstrated significant clinical activity and broad disease control
Adagrasib is a highly specific and potent oral KRAS G12C inhibitor with durable targeted inhibition
Last June, the U.
The test results show:
As of September 10, 2021, the objective response rate (ORR) for evaluable patients (n=27) was 41% and the disease control rate (DCR) was 100%
Among evaluable pancreatic cancer patients (n=10), response rate (RR) was 50%, including 1 unproven partial response (PR); median duration of response (mor) was 7.
The RR was 35% for patients with other gastrointestinal tumors (n=17), 2 of whom had undiagnosed gastrointestinal tumors; the mor for these patients was 7.
Median progression-free survival (mPFS) was 6.
Agraxib is well tolerated and has a manageable safety profile
